USFDAAug 12, 2026, 07:32 AM
PolyPid D-PLEX₁₀₀ NDA Accepted with Priority Review; $30M Upfront
AI Summary
PolyPid announced that the FDA accepted its New Drug Application (NDA) for D-PLEX₁₀₀ with Priority Review, setting a PDUFA goal date of November 28, 2026, which is ahead of previous guidance. The company also secured an exclusive U.S. and Canada commercialization partnership with Azurity Pharmaceuticals, receiving $30 million in upfront and near-term milestone payments, with potential for over $290 million in additional milestones and tiered royalties. This significantly strengthens PolyPid's financial position, with the company reporting a reduced net loss of $7.8 million for Q2 2026.
Key Highlights
- FDA accepted D-PLEX₁₀₀ NDA with Priority Review for surgical site infection prevention.
- PDUFA goal date set for November 28, 2026, approximately one quarter ahead of prior guidance.
- Entered exclusive U.S. and Canada commercialization partnership with Azurity Pharmaceuticals.
- Achieved $30 million in upfront and near-term milestone payments from Azurity.
- Eligible for over $290 million in additional milestones plus tiered royalties up to mid-twenties percentages.
- Q2 2026 net loss was $7.8 million, compared to $10.0 million in Q2 2025.
- Cash and cash equivalents were $6.6 million as of June 30, 2026, excluding $30M from Azurity.
- On track for MAA submission to EMA for D-PLEX₁₀₀ in Q3 2026.
Price Impact
More from PYPD